enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
enVVeno Medical Corporation (NASDAQ:NVNO) has appointed Jennifer Bright as Chief Financial Officer, effective May 19, 2025. Bright brings over 25 years of financial and strategic leadership experience from companies like Biolase, Spectrum Pharmaceuticals, and Teleflex Medical. She succeeds Craig Glynn, who will remain available in an advisory capacity.
The company is developing two devices for deep venous CVI treatment: the VenoValve®, a surgical replacement valve currently under FDA review with a decision expected in H2 2025, and enVVe®, a non-surgical replacement valve. enVVeno estimates a U.S. market of 2.5 million potential patients annually, including 1.5 million with active venous ulcers. The company plans to file an IDE for enVVe pivotal trial in Q3 2025.
enVVeno Medical Corporation (NASDAQ:NVNO) ha nominato Jennifer Bright come Chief Financial Officer, con effetto dal 19 maggio 2025. Bright vanta oltre 25 anni di esperienza nella leadership finanziaria e strategica in aziende come Biolase, Spectrum Pharmaceuticals e Teleflex Medical. Succede a Craig Glynn, che resterà a disposizione in veste di consulente.
L'azienda sta sviluppando due dispositivi per il trattamento della CVI venosa profonda: il VenoValve®, una valvola chirurgica sostitutiva attualmente in fase di revisione FDA, con una decisione attesa nella seconda metà del 2025, e enVVe®, una valvola sostitutiva non chirurgica. enVVeno stima un mercato statunitense di 2,5 milioni di pazienti potenziali ogni anno, di cui 1,5 milioni con ulcere venose attive. L'azienda prevede di presentare una richiesta IDE per lo studio pivotale di enVVe nel terzo trimestre 2025.
enVVeno Medical Corporation (NASDAQ:NVNO) ha nombrado a Jennifer Bright como Directora Financiera, con efecto a partir del 19 de mayo de 2025. Bright aporta más de 25 años de experiencia en liderazgo financiero y estratégico en empresas como Biolase, Spectrum Pharmaceuticals y Teleflex Medical. Sustituye a Craig Glynn, quien permanecerá disponible en calidad de asesor.
La compañía está desarrollando dos dispositivos para el tratamiento de la CVI venosa profunda: el VenoValve®, una válvula quirúrgica de reemplazo actualmente bajo revisión de la FDA, con una decisión esperada en la segunda mitad de 2025, y enVVe®, una válvula de reemplazo no quirúrgica. enVVeno estima un mercado estadounidense de 2.5 millones de pacientes potenciales anualmente, incluyendo 1.5 millones con úlceras venosas activas. La empresa planea presentar una solicitud IDE para el ensayo pivotal de enVVe en el tercer trimestre de 2025.
enVVeno Medical Corporation (NASDAQ:NVNO)는 2025년 5월 19일부로 Jennifer Bright를 최고재무책임자(CFO)로 임명했습니다. Bright는 Biolase, Spectrum Pharmaceuticals, Teleflex Medical 등에서 25년 이상의 재무 및 전략적 리더십 경험을 보유하고 있습니다. 그녀는 Craig Glynn의 후임으로, Glynn은 자문 역할로 남아 있습니다.
회사는 심부 정맥 만성 정맥 기능 부전(CVI) 치료를 위한 두 가지 장치를 개발 중입니다: 현재 FDA 심사 중이며 2025년 하반기 결정이 예상되는 수술용 교체 판막 VenoValve®와 비수술용 교체 판막 enVVe®입니다. enVVeno는 미국 내 연간 잠재 환자 수를 250만 명으로 추산하며, 이 중 150만 명은 활동성 정맥 궤양 환자입니다. 회사는 2025년 3분기에 enVVe의 주요 임상시험을 위한 IDE 신청을 계획하고 있습니다.
enVVeno Medical Corporation (NASDAQ:NVNO) a nommé Jennifer Bright au poste de Directrice Financière, à compter du 19 mai 2025. Bright apporte plus de 25 ans d'expérience en leadership financier et stratégique dans des entreprises telles que Biolase, Spectrum Pharmaceuticals et Teleflex Medical. Elle succède à Craig Glynn, qui restera disponible en tant que conseiller.
L'entreprise développe deux dispositifs pour le traitement de la CVI veineuse profonde : le VenoValve®, une valve de remplacement chirurgicale actuellement en cours d'examen par la FDA, avec une décision attendue au second semestre 2025, et le enVVe®, une valve de remplacement non chirurgicale. enVVeno estime un marché américain de 2,5 millions de patients potentiels chaque année, dont 1,5 million souffrant d'ulcères veineux actifs. La société prévoit de déposer une demande IDE pour l'essai pivot de enVVe au troisième trimestre 2025.
enVVeno Medical Corporation (NASDAQ:NVNO) hat Jennifer Bright mit Wirkung zum 19. Mai 2025 zur Chief Financial Officer ernannt. Bright bringt über 25 Jahre Erfahrung in Finanz- und strategischer Führung von Unternehmen wie Biolase, Spectrum Pharmaceuticals und Teleflex Medical mit. Sie folgt auf Craig Glynn, der weiterhin in beratender Funktion zur Verfügung steht.
Das Unternehmen entwickelt zwei Geräte zur Behandlung der tiefen venösen CVI: das VenoValve®, ein chirurgisches Ersatzventil, das derzeit von der FDA geprüft wird und dessen Entscheidung für das zweite Halbjahr 2025 erwartet wird, sowie enVVe®, ein nicht-chirurgisches Ersatzventil. enVVeno schätzt den US-Markt auf jährlich 2,5 Millionen potenzielle Patienten, davon 1,5 Millionen mit aktiven venösen Geschwüren. Das Unternehmen plant, im dritten Quartal 2025 einen IDE-Antrag für die entscheidende Studie von enVVe einzureichen.
- Appointment of experienced CFO with 25+ years in medical device and pharmaceutical companies
- Large market potential with 2.5 million annual potential patients in the U.S.
- VenoValve FDA decision expected in H2 2025
- Strategic timing of appointment as company transitions from development to commercial stage
- Products still in development phase with no current commercial revenue
- FDA approval for VenoValve still pending
- enVVe device still requires IDE approval before beginning pivotal trial
IRVINE, CA / ACCESS Newswire / May 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, announced the appointment of Jennifer Bright as Chief Financial Officer, effective today, May 19, 2025. Ms. Bright brings more than 25 years of financial and strategic leadership experience built across several commercial-stage medical device and pharmaceutical companies including Biolase, Spectrum Pharmaceuticals, Apria Healthcare, Smile Brands, and Teleflex Medical, as well as technical accounting and auditing experience at PricewaterhouseCoopers LLP.
"Jennifer brings a wealth of commercial experience to the CFO role, which we believe will be instrumental as we transition from a development-stage company to a commercial entity," said Robert Berman, enVVeno Medical's Chief Executive Officer. "In addition to overseeing our financial strategy and operations, Jennifer will play a critical role in strengthening our financial infrastructure, supporting our commercialization efforts for VenoValve, and expanding our relationships with institutional investors and analysts. Her experience navigating growth and change will be a valuable asset as we enter this next phase of the Company's evolution."
Ms. Bright is a Certified Public Accountant and received a B.A. degree in Business Administration, Accounting, from the University of Washington. She succeeds Craig Glynn, who will continue to be available to the Company in an advisory capacity.
The Company is currently developing two devices for the treatment of deep venous CVI, a potential first-in-class surgical replacement venous valve called the VenoValve®, and a non-surgical replacement venous valve called enVVe®. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for replacement venous valves, including approximately 1.5 million with active venous ulcers. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025. In the third quarter of 2025, the Company expects to file an Investigational Device Exemption (IDE) seeking authorization from the FDA to begin enVVe pivotal trial.
About CVI
Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous CVI. The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025 and is currently performing the final testing necessary to seek approval from the FDA for the enVVe pivotal trial.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
###
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire
FAQ
Who is the new CFO of enVVeno Medical (NVNO) and when does she start?
What are the main products being developed by enVVeno Medical (NVNO)?
When is the FDA decision expected for enVVeno Medical's (NVNO) VenoValve?
What is the market potential for enVVeno Medical's (NVNO) venous valve treatments?
What are the next regulatory steps for enVVeno Medical's (NVNO) enVVe device?
